Assessment of mean platelet volume in type 2 diabetics receiving insulin or oral antidiabetic agents

Yıl 2015, Cilt: 42 Sayı: 4, 399 - 403, 08.01.2016

Fatih Şahpaz Kemal Ulutaş

https://doi.org/10.5798/diclemedj.0921.2015.04.0598

Cited By: 2

Öz

Objective: Increased mean platelet volume (MPV) is a known risk factor for various acute vascular complications, which is commonly associated with patients with diabetes mellitus (DM). This study was aimed to investigate the association of MPV, Type 2 DM and to know the difference of MPV in patients on oral hypoglycemic drugs and insulin therapy.

Methods: A total of 300 patients were selected and allocated to three subgroups with 100, as DM Group on insulin therapy, DM Group on oral hypoglycemic therapy and non-DM Group (Negative control Group). Investigations like fasting blood glucose, HbA1c and MPV were performed. The results of patient values were evaluated retrospectively.

Results: Results of the study showed that patients with type 2 DM have increased in the MPV. Oral antidiabetic treatment in patients MPV, was found to be higher compared to patients treated with insulin. The mean MPV in Group 1 (on oral hypoglycemic treatment) was 10.07±0.7 fl, in Group 2 (on Insulin therapy) 9.01±0.6 fl and in the controls Group 8.15±0.8 fl.

Conclusion: The outcome of study has shown that values of MPV are increased in patients with, Type 2 DM and are significantly higher in those patients on oral hypoglycemic therapy than patients on insulin therapy. MPV is a simple and cost-effective tool which can be explored for predicting the possibility of vascular events in patients suffering from diabetes mellitus. Early initiation of insulin treatment in confirmed cases of Type 2 diabetics not only helps in controlling blood glucose level but also helps in keeping MPV low and thereby preventing possibility of impending vascular events.

Key words: Mean platelet volume, type 2 diabetes mellitus, insulin therapy, oral hypoglycemic drugs

Anahtar Kelimeler

-

Fatih Şahpaz1 Kemal Türker Ulutaş2

Öz

Amaç: Artmış Ortalama Trombosit Hacmi (OTH), Diabetes Mellitus (DM) hastalarında yaygın vasküler komplikasyonlarla yakından ilişkilidir. Bu çalışma OTH ile insulin tedavisi alan veya oral hipoglisemik tedavi alan hastaları kıyaslamayı amaçlamaktadır. Yöntemler: Çalışmaya randomize olarak seçilen 300 hasta 100 kişilik üç gruba ayrıldı: oral hipoglisemik tedavi alan grup-1, insulin tedavisi alan DM grup-2 ve non-DM sağlıklı grup-3. Tüm hastalardan açlık kan şekeri, HbA1c ve OTH ve biyokimya değerleri retrospektif olarak değerlendirildi.Bulgular: Çalışma sonucu OTH değerlerinin Tip 2 DM olan hastalarda artmış olduğu göstermiştir ve oral antidiyabetik tedavi alan hastalarda, insulin tedavisi alan hastalara göre daha yüksek olarak saptanmıştır. OTH değeri grup 1’de (oral hipoglisemik tedavi alan) 10.07±0.7fl, grup 2’de (İnsülin tedavisi alan) 9.01±0.6fl ve kontrol grubunda 8.15±0.8fl olarak tespit edildi. Sonuç: Çalışma sonucu DM hastası olgularda vasküler hastalık olasılığını tahmin etmek için OTH basit ve düşük maliyetli-etkin bir tanı aracı olarak kullanılabileceğini düşündürmektedir. Tip 2 diyabet doğrulanmış olgularda insulin tedavisinin erken başlanması sadece kan şekeri düzeyini kontrol etmede yardımcı olmaz; aynı zamanda OTH seviyesini düşük tutarak yaklaşan vasküler olayların olma olasılığını önlemeye yardımcı olabilir

Anahtar Kelimeler

Ortalama trombosit hacmi, tip 2 diabetes mellitus, insülin tedavisi, oral hipoglisemik ilaçlar

Kaynakça

• Mahsud MAJ, Khan A, Hussain J. Hematological changes in tobacco using type 2 diabetic patients. Gomal J Med Sci 2010;8:8-11.
• King H, Aubert RE, Herman WH. Global burden of diabetes,1995-2025: prevalence, numerical estimates, and projections. Diabetes Care1998;21:1414-1431.
• Demirtunc R, Duman D, Basar M, et al. The relationship between glycemic control and platelet activity in type 2 diabetes mellitus. J Diabetes Complications 2009;23:89-94.
• Hekimsoy Z, Payzinb B, Ornek T, et al. Mean platelet volume in Type 2 diabetic patients. J Diabetes Complications 2004;18:173-176.
• Zuberi BF, Akhtar N, Afsar S. Comparison of mean platelet volume in patients with diabetes mellitus, impaired fasting glucose and non-diabetic subjects. Singapore Med J 2008;49:114-116.
• Chamberlain KG, Tong M, Chiu E, et al. The relationship of human platelet density to platelet age: platelet population labeling bymonoamine oxidase inhibition. Blood 1989;73:1218-1225.
• Martin J. The relationship between megakaryocyte ploidy and platelet volume. Blood Cells 1989;15:108-121.
• Tavil Y, Sen N, Yazici HU, et al. Mean platelet volume in patients with metabolic syndrome and its relationship with coronary artery disease. Thromb Res 2007;120:245-250.
• Khandekar MM, Khurana AS, Deshmukh SD, et al. Platelet volume indices in patients with coronary artery disease and acute myocardial infarction: an Indian scenario. J Clin Pathol 2006;59:146-149.
• O’Malley T, Langhorne P, Elton RA, et al. Platelet size in stroke patients. Stroke 1995;26:995-999.
• Bock G, Dalla Man C, Campioni M, et al. Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 2006;55:3536-3549.
• Papanas N, Symeonidis G, Maltezos E, et al. Mean platelet volume in patients with type 2 diabetes mellitus. Platelets 2004; 15:475-478.
• Hekimsoy Z, Payzin B, Ornek T, et al. Mean platelet volume in Type 2 diabetic patients. J Diabetes Complications 2004; 18:173-176.
• Kim KY, Kim KE, Kim KH. Mean platelet volume in the normal state and in various clinical disorders. Yonsei Med J 1986;27:219-226.
• Satman I, Yilmaz T, Sengul A, et al. The TURDEP Group. Population-based study of diabetes and risk characteristics in Turkey: results of the Turkish diabetes epidemiology study (TURDEP). Diabetes Care 2002;25:1551-1556.
• Khuwaja AK, Rafique G, White F, et al. Macrovascular complications and their associated factors among persons with Type 2 diabetes in Karachi, Pakistan-a multi-center study. J Pak Med Assoc. 2004;54:60-66.
• Kodiatte TA, Manikyam UK, Rao SB, et al. Mean Platelet Volume in Type 2 Diabetes Mellitus, J Lab Physicians 2012;4:5-9.
• Colwell JA, Nesto RW. The platelet in diabetes-focus on revention
• of ischemic events. Diabetes Care 2003;26:2181-2188.
• Chang HA, Hwang HS, Park HK, et al. The role of mean platelet volume as a predicting factor of asymptomatic coronary artery disease. Korean J Fam Med 2010;31:600-606.
• Bae SH, Lee J, Roh KH, et al. J. Platelet activation in patients
• with diabetic retinopathy. Korean J Ophthalmol 2003;17:140-144.
• Zuberi BF, Akhtar N, Afsar S. Comparison of mean platelet volume in patients with diabetes mellitus, impaired fasting glucose and non-diabetic subjects. Singapore Med J
• Jindal S, Gupta S, Gupta R, at al. Platelet indices in diabetes
• mellitus: indicators of diabetic microvascular complications. Hematology 2011;16:86-89.
• Arauz-Pacheco C, Parrott MA, Raskin P. The treatment of
• hypertension in adult patients with diabetes. Diabetes Care 2002;25:134-147.
• Jabeen F, Fawwad A, Rizvi HA, et al. Role of platelet indices,
• glycemic control and hs-CRP in pathogenesis of vascular complications in type-2 diabetic patients. Pak J Med Sci 2013;29:152-156.
• Vernekar PV, Vaidya KA. Comparison of mean platelet volume
• in type 2 diabetics on insulin therapy and on oral hypoglycaemic
• agents. J Clin Diagn Res 2013;12:2839-2840.
• Yenigün EC, Okyay GU, Pirpir A, et al. Increased mean platelet volume in type 2 diabetes mellitus. Dicle Tıp Dergisi 2014;41:17-22.